Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. US Specialty Formulations LLC
483
•US Specialty Formulations LLC•July 2, 2024

US Specialty Formulations LLC – FDA 483, Jul 2, 2024

Record Details

This FDA Form 483 details seven observations from an inspection. The facility failed to ensure its quality control unit had the authority to approve/reject materials and products. Specifically, the potency of finished Sanacenia Purpurea 0.17g/ml drug product and bulk distillate was not determined prior to release, despite approximately [(b) (4)] vials of the injection drug product being released since June 2022.

Laboratory controls lacked determination of conformance to specifications for components. The written stability program for drug products did not include reliable, meaningful, and specific test methods. The established testing specification for Sanacenia Purpurea 0.17g/ml injection drug product failed to provide adequate stability data to support the labeled 12-month expiry date, and test methods were not stability-indicating. Additionally, adequate data was not provided to support the 12-month retest date for the Bulk Sanacenia.

Testing and release of drug product for distribution did not include appropriate laboratory determination of satisfactory conformance to final specifications, identity, and strength of each active ingredient prior to release. Approximately [redacted] batches of bulk distillate and [redacted] vials of finished injection drug product were released without a test method to determine potency or concentration of active ingredients.

Procedures designed to prevent microbiological contamination of sterile drug products were not followed. Reserve samples were not visually examined annually for deterioration. The firm failed to thoroughly review unexplained discrepancies and batch

Company
US Specialty Formulations LLC
Inspection date
July 2, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Ucheabuchi C. Chudi-Nwankwor
View Company Profile

ID · 02180e72-25a9-4bdf-970c-9567cf7a7ce8

Other documents for US Specialty Formulations LLC
  • 483 - 2025-03-26March 26, 2025
  • 483 - 2022-04-26April 26, 2022
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore US Specialty Formulations LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.